What Happened?

Shares of specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) jumped 13.4% in the pre-market session after the company reported strong fourth-quarter 2024 results, significantly surpassing analysts' revenue expectations. Revenue surged 45% year-on-year, fueled by continued growth in its Rare Disease segment. Purified Cortrophin Gel led the way with a 42% rise, while the newly added ILUVIEN and YUTIQ products also boosted sales. The company raised its 2025 outlook, now expecting sales to climb up to 26% and earnings per share to grow as much as 25%. Overall, the quarter showed strong sales growth and smart investments.

Is now the time to buy ANI Pharmaceuticals? Access our full analysis report here, it’s free.

What The Market Is Telling Us

ANI Pharmaceuticals’s shares are not very volatile and have only had 7 moves greater than 5% over the last year. Moves this big are rare for ANI Pharmaceuticals and indicate this news significantly impacted the market’s perception of the business.

ANI Pharmaceuticals is up 9% since the beginning of the year, but at $60.43 per share, it is still trading 13.3% below its 52-week high of $69.69 from March 2024. Investors who bought $1,000 worth of ANI Pharmaceuticals’s shares 5 years ago would now be looking at an investment worth $1,259.

Today’s young investors likely haven’t read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.